Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs iShares Silver Trust — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.5 (market cap $5.85B), while iShares Silver Trust trades at $54.53 (market cap $29.58B). The key difference: iShares Silver Trust is far larger — about 5.1× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and iShares Silver Trust for 89 Days on average.
| IOVA | SLV | |
|---|---|---|
Market Cap | $5.85B | $29.58B |
Volume | 14,517,176 | 20,364,955 |
Sector | Health | — |
52-Week High | $14.82 | $105.57 |
52-Week Low | $1.81 | $42.40 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $5.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SLV (iShares Silver Trust) is trading at $53.82, down 2.94% amid broader precious metals pressure from rising Treasury yields and Fed rate hike expectations. The ETF shows minimal operational activity with $0 revenue but maintains a strong balance sheet with $13.41 billion in assets against negligible liabilities. Technical indicators signal bearish momentum with moving averages overwhelmingly negative, though RSI levels suggest potential oversold conditions.
While silver faces near-term headwinds from monetary policy, structural demand from industrial applications and inflation hedging provides long-term support. Key risks include Fed policy volatility and dollar strength, but the trust's pure-play silver exposure offers strategic diversification. Current levels may present accumulation opportunities for investors with multi-year horizons.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
